{"id":3912,"date":"2026-09-10T22:04:40","date_gmt":"2026-09-11T02:04:40","guid":{"rendered":"https:\/\/revivelongevity.com\/are-peptides-safe\/"},"modified":"2026-09-10T22:04:52","modified_gmt":"2026-09-11T02:04:52","slug":"are-peptides-safe","status":"publish","type":"post","link":"https:\/\/revivelongevity.com\/ru\/are-peptides-safe\/","title":{"rendered":"Are Peptides Safe? What the Evidence Says and What Makes the Difference"},"content":{"rendered":"<div class=\"blog-takeaways\">\n<h2>\u041a\u043b\u044e\u0447\u0435\u0432\u044b\u0435 \u0432\u044b\u0432\u043e\u0434\u044b<\/h2>\n<ul>\n<li>Whether a peptide is safe depends on its source: FDA-approved peptide drugs have measured side-effect rates in their labels, compounded peptides are not FDA-approved, and peptides sold online as research chemicals have no safety oversight at all.<\/li>\n<li>In the three placebo-controlled trials pooled in Wegovy&#8217;s label, which included 2,116 adults with obesity or overweight treated with 2.4 mg for up to 68 weeks, nausea occurred in 44% of patients versus 16% on placebo, and 6.8% stopped treatment for adverse reactions versus 3.2% on placebo.<\/li>\n<li>As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide, figures FDA says are likely underreported and that do not establish causation.<\/li>\n<li>A laboratory screening of the ten most frequently encountered falsified peptide drugs on the Belgian market found purity from 5% to 75% for cysteine-containing peptides and multiple samples carrying arsenic concentrations up to ten times the ICH toxicity limit for parenteral (injectable) drugs.<\/li>\n<li>BPC-157, TB-500, CJC-1295 and ipamorelin are not FDA-approved, none of them appears on the 503A bulks list at 21 CFR 216.23, and none has Category 1 interim status, so FDA&#8217;s interim policy does not reach them. FDA has evaluated each of them as a nominated bulk substance, a process that applies only where no applicable USP or NF monograph exists and the substance is not a component of an approved drug, so no 503A route is open to them. Revive does not offer them.<\/li>\n<\/ul>\n<\/div>\n<h2>Are peptides safe?<\/h2>\n<p>The answer depends on three things: which peptide, where it came from, and whether a licensed provider is screening and monitoring you. FDA-approved peptide drugs carry full labels with measured side-effect rates. Compounded peptides are not FDA-approved, so safety rests on the prescriber and the pharmacy. Peptides sold online as research chemicals have no safety oversight at all.<\/p>\n<h2>What a peptide is, and why the source changes the answer<\/h2>\n<p>A peptide is a short chain of amino acids, the building blocks of proteins. Semaglutide and tirzepatide, the GLP-1 medications for diabetes and obesity, are peptides, and so is bremelanotide (Vyleesi). People asking whether peptides are safe usually mean the injectables marketed online for recovery, muscle, fat loss or anti-aging.<\/p>\n<p>In the United States, a product sold to change how the body works is a drug, whatever the label says. In an August 2026 warning letter to an online peptide seller, FDA wrote that despite labeling the vials &#8220;for research use only&#8221; and &#8220;not for human or veterinary use,&#8221; evidence from the seller&#8217;s website &#8220;establishes that your products are intended to be drugs for human use.&#8221;<\/p>\n<figure class=\"blog-inline\"><img loading=\"lazy\" width=\"800\" height=\"534\" src=\"https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i1-2-1024x683.png\" class=\"attachment-large size-large\" alt=\"Abstract scientific visualization of three translucent layered forms representing three levels of oversight, from fully verified to unverified\" decoding=\"async\" srcset=\"https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i1-2-1024x683.png 1024w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i1-2-300x200.png 300w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i1-2-768x512.png 768w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i1-2-1536x1024.png 1536w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i1-2-18x12.png 18w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i1-2-600x400.png 600w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i1-2.png 2016w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><figcaption>The same peptide can arrive as an FDA-approved drug, a compounded prescription, or an unregulated research chemical, with very different levels of verification behind each.<\/figcaption><\/figure>\n<h2>Three sources, three levels of oversight<\/h2>\n<p>The table uses FDA&#8217;s descriptions.<\/p>\n<table>\n<thead>\n<tr>\n<th>\u0418\u0441\u0442\u043e\u0447\u043d\u0438\u043a<\/th>\n<th>Who reviews it<\/th>\n<th>What is verified<\/th>\n<th>Typical risks<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>FDA-approved peptide drug (Wegovy, Zepbound, Vyleesi)<\/td>\n<td>FDA reviews safety, effectiveness and quality before marketing<\/td>\n<td>Adverse-reaction rates from defined trial populations, plus label warnings and dosing<\/td>\n<td>Class effects (such as gastrointestinal reactions with GLP-1 medicines) and the rarer serious events the label lists<\/td>\n<\/tr>\n<tr>\n<td>Compounded prescription peptide (503A pharmacy)<\/td>\n<td>No FDA review of safety, effectiveness or quality before marketing; FDA works with state regulators<\/td>\n<td>The prescriber&#8217;s evaluation and the pharmacy&#8217;s state license; no FDA-reviewed label<\/td>\n<td>Class effects, plus dosing errors, contamination, unapproved salt forms and shipping-temperature problems FDA has flagged in compounded GLP-1s<\/td>\n<\/tr>\n<tr>\n<td>Research-chemical peptide (&#8220;not for human use&#8221;)<\/td>\n<td>No one. FDA treats it as an unapproved drug whatever the label says<\/td>\n<td>Nothing. Identity, purity, sterility and dose are unverified<\/td>\n<td>Unknown purity and contamination (one screening of falsified internet peptides found 5% to 75% purity and toxic metals)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Side effects by peptide class: what the evidence shows<\/h2>\n<h3>GLP-1 and GIP receptor agonists (semaglutide, tirzepatide)<\/h3>\n<p>Wegovy&#8217;s label pools three placebo-controlled trials in 2,116 adults with obesity or overweight treated with the 2.4 mg injection for up to 68 weeks, against 1,261 on placebo. Nausea occurred in 44% versus 16% on placebo and vomiting in 24% versus 6%; 6.8% stopped treatment for adverse reactions, versus 3.2%. Zepbound&#8217;s weight-reduction trials show the same pattern: gastrointestinal adverse reactions in 56% at each dose versus 30% on placebo, and nausea in 25% to 29% versus 8%, mostly during dose escalation.<\/p>\n<p>Both labels carry a boxed warning about thyroid C-cell tumors, a rodent finding whose relevance to humans has not been determined, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. More in <a href=\"\/ru\/tirzepatide-side-effects\/\">Tirzepatide Side Effects<\/a> \u0438 <a href=\"\/ru\/is-zepbound-safe\/\">Is Zepbound Safe?<\/a>.<\/p>\n<h3>Melanocortin agonist (bremelanotide)<\/h3>\n<p>Bremelanotide, sold as Vyleesi and compounded as PT-141, is FDA-approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and the label&#8217;s Limitations of Use state that Vyleesi is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance. In the Vyleesi trials, 40% of participants reported nausea. Each dose transiently raises blood pressure (about 6 mmHg systolic and 3 mmHg diastolic at peak) and lowers heart rate, so it is contraindicated in uncontrolled hypertension or known cardiovascular disease. Any compounded PT-141, including nasal sprays and any use in men, is off-label and not FDA-approved. More in <a href=\"\/ru\/what-is-pt-141\/\">What Is PT-141?<\/a>.<\/p>\n<h3>Sermorelin: an approval that is no longer marketed<\/h3>\n<p>No FDA-approved sermorelin product is marketed today. Drugs@FDA lists two Geref (sermorelin acetate) applications from EMD Serono: NDA 019863, approved December 28, 1990, and NDA 020443, approved September 26, 1997. Both are listed as discontinued, and FDA&#8217;s records note they were not withdrawn for safety or effectiveness reasons. Every sermorelin prescription written today is compounded, so FDA has not evaluated it for safety, quality or efficacy, and no current label reports adverse-reaction rates.<\/p>\n<p>Because Geref was an FDA-approved drug and FDA&#8217;s records show it was not withdrawn for safety or effectiveness reasons, sermorelin acetate still satisfies the second 503A route, a component of an FDA-approved drug. That is why it does not appear on FDA&#8217;s Category 1 or Category 2 nominations list at all, and why it may be compounded while BPC-157 and the others may not. See <a href=\"\/ru\/sermorelin-side-effects\/\">Sermorelin Side Effects and Safety<\/a>.<\/p>\n<h2>Compounded peptides: what changes when a product is not FDA-approved<\/h2>\n<p>A 503A pharmacy prepares a drug for one patient on a prescription. Compounded drugs are not FDA-approved, so FDA does not review them for safety, effectiveness or quality before marketing. FDA says they should be used only when an approved drug cannot meet a patient&#8217;s needs, and that a 503A preparation must not be essentially a copy of a commercially available drug.<\/p>\n<p>Compounded GLP-1s usually arrive in vials the patient measures and draws with a syringe. FDA has received multiple reports of adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide: patients self-administering the wrong dose and providers miscalculating doses. FDA has also flagged unapproved salt forms such as semaglutide sodium and acetate, contamination risk when multi-dose vials are used past 28 days or needles reused, and improper refrigeration in shipping.<\/p>\n<p>As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. FDA calls those numbers likely underreported, since state-licensed pharmacies that are not outsourcing facilities need not report adverse events, and notes that causation cannot always be determined and that many reports resemble events known from the approved drugs.<\/p>\n<p>FDA sorts the substances nominated for its 503A bulks list into interim categories: Category 1 is under evaluation, and Category 2 raises significant safety risks, which puts those substances outside FDA&#8217;s Category 1 policy. Under FDA&#8217;s January 2025 interim policy guidance, the agency does not intend to act against a pharmacy or physician compounding with a bulk substance that has no USP or NF monograph and is not part of an FDA-approved drug, if four conditions hold: it appears in Category 1, its manufacturers are FDA-registered, it comes with a valid certificate of analysis, and all other 503A conditions are met. On FDA&#8217;s list updated May 14, 2026, Category 1 includes enclomiphene citrate, glutathione and nicotinamide adenine dinucleotide (NAD). Category 1 is neither approval nor statutory eligibility: those compounded products are not FDA-approved and are unevaluated for safety, quality or efficacy. See <a href=\"\/ru\/enclomiphene-side-effects\/\">Enclomiphene Side Effects<\/a>, <a href=\"\/ru\/glutathione-side-effects\/\">Glutathione Side Effects<\/a> \u0438 <a href=\"\/ru\/nad-side-effects\/\">NAD+ Side Effects<\/a>.<\/p>\n<p>Where an approved product is commercially available, routine compounding of copies is not permitted: a compounded GLP-1 fits only where a licensed provider documents an individual clinical need the approved products cannot meet. More in <a href=\"\/ru\/compounded-tirzepatide-2026\/\">Compounded Tirzepatide in 2026<\/a>.<\/p>\n<h2>Research-chemical peptides: the risks nobody is measuring<\/h2>\n<p>Websites sell peptide vials labeled &#8220;for research use only,&#8221; often with bacteriostatic water. In its August 2026 warning letter, FDA noted that selling bacteriostatic water with the vials provided &#8220;the means to prepare an injectable drug for human administration,&#8221; and that injectable products &#8220;bypass some of the body&#8217;s key defenses against toxins and microorganisms.&#8221;<\/p>\n<p>In a laboratory screening of the ten most frequently encountered falsified peptide drugs on the Belgian market, bought from three suspected illegal internet pharmacies, researchers found wide variation in drug content per unit, purity from 5% to 75% for cysteine-containing peptides, and the toxic elemental impurities arsenic and lead. Multiple samples carried arsenic up to ten times the ICH toxicity limit for parenteral (injectable) drugs, in its more toxic inorganic form. That is one study of one market, not a statistic about every vendor, but no accountable party has tested the vial in your hands either.<\/p>\n<h2>Where BPC-157, TB-500, CJC-1295 and ipamorelin stand in 2026<\/h2>\n<p>Their status has shifted more than once, and no shift has made them eligible for 503A compounding.<\/p>\n<ol>\n<li><strong>Category 2, for significant safety risks.<\/strong> Ipamorelin acetate is still listed in Category 2 for 503B compounding, dated September 29, 2023 on FDA&#8217;s list, alongside kisspeptin-10 for 503A. FDA had also placed BPC-157, TB-500, CJC-1295, AOD-9604 and MOTS-c in Category 2, and, on its page on bulk drug substances that may present significant safety risks, still publishes its concerns for each: that compounded drugs containing them may pose a risk for immunogenicity for certain routes of administration, meaning impurities or aggregates provoking an immune response, may carry peptide-related impurities and resist characterization of the active ingredient, and that there are no or only limited human safety data. FDA also cites serious adverse events reported with CJC-1295 (increased heart rate, systemic vasodilatory reaction) and ipamorelin (including a death when it was given intravenously in a gastric motility study).<\/li>\n<li><strong>After the nominations were withdrawn.<\/strong> The nominators of BPC-157, TB-500, CJC-1295, AOD-9604 and MOTS-c withdrew their nominations, so FDA moved them off Category 2. FDA&#8217;s nominations list updated May 14, 2026 shows six substances in 503A Category 2, none of them these peptides. On FDA&#8217;s safety-risks page, the withdrawn peptides sit in a &#8220;nominated but withdrawn&#8221; table, with no withdrawal dates given. Withdrawal was not approval.<\/li>\n<li><strong>Why none of them may be compounded under 503A.<\/strong> Section 503A permits a bulk drug substance by three routes only: it complies with an applicable USP or NF monograph; if no monograph exists, it is a component of an FDA-approved drug; failing both, it appears on the 503A bulks list set by regulation at 21 CFR 216.23. None of these four peptides appears on the 503A bulks list at 21 CFR 216.23, and none has Category 1 interim status, so FDA&#8217;s interim policy does not reach them. FDA has evaluated each of them as a nominated bulk substance, a process that applies only where no applicable USP or NF monograph exists and the substance is not a component of an approved drug, so no 503A route is open to them. Adding a peptide to that list would take rulemaking that amends 21 CFR 216.23, which has not happened as of September 2026.<\/li>\n<\/ol>\n<p>Revive does not offer any peptide in this group. More in <a href=\"\/ru\/fda-peptide-review-2026\/\">FDA&#8217;s 2026 peptide review<\/a>.<\/p>\n<figure class=\"blog-inline\"><img loading=\"lazy\" width=\"800\" height=\"534\" src=\"https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i2-2-1024x683.png\" class=\"attachment-large size-large\" alt=\"A woman in her thirties at a wooden desk by a window during a video consultation, taking notes in a paper notebook\" decoding=\"async\" srcset=\"https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i2-2-1024x683.png 1024w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i2-2-300x200.png 300w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i2-2-768x512.png 768w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i2-2-1536x1024.png 1536w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i2-2-18x12.png 18w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i2-2-600x400.png 600w, https:\/\/revivelongevity.com\/wp-content\/uploads\/2026\/09\/i2-2.png 2016w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><figcaption>Screening for contraindications, baseline labs and scheduled follow-up are what separate supervised prescription therapy from an unsupervised purchase.<\/figcaption><\/figure>\n<h2>Contraindications, red flags and what monitoring looks like<\/h2>\n<h3>Who should not use peptides<\/h3>\n<p>Contraindications are peptide-specific. From the approved labels:<\/p>\n<ul>\n<li><strong>GLP-1 and GIP agonists:<\/strong> a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2. The labels also warn about pancreatitis and gallbladder disease, and Wegovy advises stopping at least two months before a planned pregnancy.<\/li>\n<li><strong>Bremelanotide (PT-141):<\/strong> uncontrolled hypertension or known cardiovascular disease, because each dose raises blood pressure for hours.<\/li>\n<li><strong>Any compounded or research-chemical peptide:<\/strong> no FDA-reviewed label exists for the compounded product itself, so FDA has not evaluated its pregnancy, breastfeeding or long-term safety. Where a compounded drug copies an approved one, that label&#8217;s warnings still inform screening; where there is no currently marketed approved counterpart, such as sermorelin, there are no label-reported adverse-reaction rates or pregnancy and long-term safety data to screen against. For the peptides on FDA&#8217;s Category 2 and nominated-but-withdrawn lists, including BPC-157, TB-500, CJC-1295 and ipamorelin, FDA reports no, or only limited, safety information for the proposed routes of administration. The provider&#8217;s history-taking is the only screen you get.<\/li>\n<\/ul>\n<h3>Red flags when buying online<\/h3>\n<p>Two red flags are specific to peptides: a &#8220;research use only&#8221; label on a product sold with dosing guidance, and any claim that a compounded peptide is &#8220;FDA-approved.&#8221; FDA&#8217;s warning signs for buying medicine online apply too.<\/p>\n<h3>What monitoring looks like<\/h3>\n<p>A careful prescriber takes a health history and medication review, orders baseline labs where relevant, checks blood pressure before any medication that affects it, follows the label&#8217;s dose-escalation schedule where one exists, schedules follow-up, and asks you to report suspected side effects promptly.<\/p>\n<h2>How Revive approaches peptide safety<\/h2>\n<p>Revive Longevity is a LegitScript-certified clinic with licensed providers in all 50 states. Prescription therapies are dispensed only after a licensed provider reviews your health history, medications and goals, orders any labs the therapy calls for, and decides whether treatment is appropriate. Prescriptions are filled for the individual patient by state-licensed 503A compounding pharmacies, and compounded medications are not FDA-approved. Revive does not offer BPC-157, TB-500, CJC-1295, ipamorelin or any peptide that is not eligible for 503A compounding, and nothing is sold &#8220;for research.&#8221;<\/p>\n<p>Content on this site is reviewed by <a href=\"\/ru\/diana-medina\/\">Diana Medina, PA-C<\/a>, a board-certified Physician Associate. Product pages list pricing per 4 weeks (Sermorelin $179, Enclomiphene $159); pricing is subject to change and eligibility. The full process is described on <a href=\"\/ru\/how-it-works\/\">how Revive works<\/a>.<\/p>\n<h2>\u0427\u0430\u0441\u0442\u043e \u0437\u0430\u0434\u0430\u0432\u0430\u0435\u043c\u044b\u0435 \u0432\u043e\u043f\u0440\u043e\u0441\u044b<\/h2>\n<h3>Are peptides FDA-approved?<\/h3>\n<p>Some are. Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and bremelanotide (Vyleesi) are FDA-approved peptide drugs with full labels. Compounded peptides, including sermorelin, are not FDA-approved. BPC-157, TB-500, CJC-1295 and ipamorelin are not FDA-approved, none of them appears on the 503A bulks list at 21 CFR 216.23, and none has Category 1 interim status, so FDA&#8217;s interim policy does not reach them. FDA has evaluated each of them as a nominated bulk substance, a process that applies only where no applicable USP or NF monograph exists and the substance is not a component of an approved drug, so no 503A route is open to them.<\/p>\n<h3>Are compounded peptides safe?<\/h3>\n<p>They can be appropriate when a licensed provider determines an individual need and a state-licensed 503A pharmacy fills the prescription, but they are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before marketing. Risks FDA has reported for compounded GLP-1s include dosing errors, contamination from multi-dose vials and needle reuse, unapproved salt forms and improper refrigeration in shipping.<\/p>\n<h3>Is BPC-157 legal or FDA-approved in 2026?<\/h3>\n<p>BPC-157 is not FDA-approved. FDA placed it in Category 2 for significant safety risks, and after its nomination was withdrawn it moved to FDA&#8217;s nominated-but-withdrawn list, where FDA still publishes its safety concerns. BPC-157 does not appear on the 503A bulks list at 21 CFR 216.23, and it has no Category 1 interim status, so FDA&#8217;s interim policy does not reach it. FDA has evaluated BPC-157 as a nominated bulk substance, a process that applies only where no applicable USP or NF monograph exists and the substance is not a component of an approved drug, so no 503A route is open to it and it may not be compounded under 503A. Revive does not offer BPC-157.<\/p>\n<h3>What are the most common side effects of peptides?<\/h3>\n<p>It depends on the class. In the Wegovy label&#8217;s pool of three placebo-controlled trials in adults with obesity or overweight, nausea occurred in 44% on Wegovy 2.4 mg versus 16% on placebo; in Zepbound&#8217;s weight-reduction trials, gastrointestinal adverse reactions occurred in 56% versus 30% on placebo. In the Vyleesi trials in premenopausal women with HSDD, 40% of participants reported nausea, and each dose transiently raised blood pressure. No comparable label data exist for compounded or research-chemical peptides.<\/p>\n<h3>How can I tell whether an online peptide seller is legitimate?<\/h3>\n<p>Use FDA&#8217;s warning signs. Be cautious if a company does not require screening and a prescription from a licensed doctor, claims a compounded drug is the same as an FDA-approved drug, offers prices that seem too good to be true, or has no licensed doctor available to answer questions. FDA advises getting a prescription from your doctor and filling it at a state-licensed pharmacy. Verify credentials directly with the relevant state board.<\/p>\n<div class=\"blog-cta\">\n<h2>Talk with a licensed provider before starting any peptide<\/h2>\n<p>A Revive provider reviews your history, orders any labs your situation calls for, and decides whether a prescription therapy is appropriate.<\/p>\n<p><a class=\"blog-cta-btn\" href=\"\/ru\/how-it-works\/\">\u0423\u0437\u043d\u0430\u0439\u0442\u0435, \u043a\u0430\u043a \u0440\u0430\u0431\u043e\u0442\u0430\u0435\u0442 Revive &rarr;<\/a><\/p>\n<p class=\"blog-cta-fine\">\u0422\u043e\u043b\u044c\u043a\u043e \u043e\u0431\u0440\u0430\u0437\u043e\u0432\u0430\u0442\u0435\u043b\u044c\u043d\u0430\u044f \u0438\u043d\u0444\u043e\u0440\u043c\u0430\u0446\u0438\u044f, \u043d\u0435 \u044f\u0432\u043b\u044f\u044e\u0449\u0430\u044f\u0441\u044f \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u043e\u0439 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0435\u0439. \u0420\u0435\u0446\u0435\u043f\u0442\u0443\u0440\u043d\u043e\u0435 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u0442\u0440\u0435\u0431\u0443\u0435\u0442 \u043a\u043e\u043d\u0441\u0443\u043b\u044c\u0442\u0430\u0446\u0438\u0438 \u0441 \u043b\u0438\u0446\u0435\u043d\u0437\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u043c \u0432\u0440\u0430\u0447\u043e\u043c, \u043a\u043e\u0442\u043e\u0440\u044b\u0439 \u043e\u043f\u0440\u0435\u0434\u0435\u043b\u044f\u0435\u0442, \u044f\u0432\u043b\u044f\u0435\u0442\u0441\u044f \u043b\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u0446\u0435\u043b\u0435\u0441\u043e\u043e\u0431\u0440\u0430\u0437\u043d\u044b\u043c. \u041d\u0435\u043a\u043e\u0442\u043e\u0440\u044b\u0435 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u044b \u043c\u043e\u0433\u0443\u0442 \u0438\u0437\u0433\u043e\u0442\u0430\u0432\u043b\u0438\u0432\u0430\u0442\u044c\u0441\u044f \u043f\u043e \u0438\u043d\u0434\u0438\u0432\u0438\u0434\u0443\u0430\u043b\u044c\u043d\u043e\u043c\u0443 \u0440\u0435\u0446\u0435\u043f\u0442\u0443 (\u043a\u043e\u043c\u043f\u0430\u0443\u043d\u0434\u0438\u0440\u043e\u0432\u0430\u0442\u044c\u0441\u044f); \u043a\u043e\u043c\u043f\u0430\u0443\u043d\u0434\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u0435 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u044b \u043d\u0435 \u043e\u0434\u043e\u0431\u0440\u0435\u043d\u044b FDA, \u0438 FDA \u043d\u0435 \u043e\u0446\u0435\u043d\u0438\u0432\u0430\u043b\u043e \u0438\u0445 \u043d\u0430 \u043f\u0440\u0435\u0434\u043c\u0435\u0442 \u0431\u0435\u0437\u043e\u043f\u0430\u0441\u043d\u043e\u0441\u0442\u0438, \u043a\u0430\u0447\u0435\u0441\u0442\u0432\u0430 \u0438\u043b\u0438 \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u0438. \u0418\u043d\u0434\u0438\u0432\u0438\u0434\u0443\u0430\u043b\u044c\u043d\u044b\u0435 \u0440\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u043c\u043e\u0433\u0443\u0442 \u043e\u0442\u043b\u0438\u0447\u0430\u0442\u044c\u0441\u044f.<\/p>\n<\/div>\n<div class=\"blog-takeaways blog-related\">\n<h2>\u041f\u043e\u0445\u043e\u0436\u0438\u0435 \u043c\u0430\u0442\u0435\u0440\u0438\u0430\u043b\u044b<\/h2>\n<ul>\n<li><a href=\"\/ru\/fda-peptide-review-2026\/\">The FDA July 2026 Peptide Review<\/a><\/li>\n<li><a href=\"\/ru\/best-online-peptide-therapy-clinics-2026\/\">Best Online Peptide Therapy Clinics of 2026<\/a><\/li>\n<li><a href=\"\/ru\/compounded-tirzepatide-2026\/\">Compounded Tirzepatide in 2026<\/a><\/li>\n<li><a href=\"\/ru\/peptides-for-weight-loss\/\">Peptides for Weight Loss: A 2026 Guide<\/a><\/li>\n<\/ul>\n<\/div>\n<div class=\"blog-sources\">\n<h2>\u0418\u0441\u0442\u043e\u0447\u043d\u0438\u043a\u0438<\/h2>\n<ol>\n<li>FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Updated May 14, 2026) <a href=\"https:\/\/www.fda.gov\/media\/94155\/download\" target=\"_blank\" rel=\"noopener\">fda.gov<\/a><\/li>\n<li>FDA: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&#038;C Act, Guidance for Industry (January 2025) <a href=\"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and\" target=\"_blank\" rel=\"noopener\">fda.gov<\/a><\/li>\n<li>FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks <a href=\"https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks\" target=\"_blank\" rel=\"noopener\">fda.gov<\/a><\/li>\n<li>eCFR: 21 CFR 216.23, Bulk Drug Substances That Can Be Used to Compound Under Section 503A <a href=\"https:\/\/www.ecfr.gov\/current\/title-21\/section-216.23\" target=\"_blank\" rel=\"noopener\">ecfr.gov<\/a><\/li>\n<li>FDA: FDA&#8217;s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss <a href=\"https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss\" target=\"_blank\" rel=\"noopener\">fda.gov<\/a><\/li>\n<li>FDA: Warning Letter to Peptide Partners LLC (August 24, 2026) <a href=\"https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/peptide-partners-llc-735063-08242026\" target=\"_blank\" rel=\"noopener\">fda.gov<\/a><\/li>\n<li>Janvier S, et al., Talanta (2018): Impurity Profiling of the Most Frequently Encountered Falsified Polypeptide Drugs on the Belgian Market <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30029448\/\" target=\"_blank\" rel=\"noopener\">pubmed.ncbi.nlm.nih.gov<\/a><\/li>\n<li>DailyMed (NIH): WEGOVY (semaglutide) Prescribing Information <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b\" target=\"_blank\" rel=\"noopener\">dailymed.nlm.nih.gov<\/a><\/li>\n<li>DailyMed (NIH): ZEPBOUND (tirzepatide) Prescribing Information <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b\" target=\"_blank\" rel=\"noopener\">dailymed.nlm.nih.gov<\/a><\/li>\n<li>FDA: VYLEESI (bremelanotide injection) Prescribing Information <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210557s000lbl.pdf\" target=\"_blank\" rel=\"noopener\">accessdata.fda.gov<\/a><\/li>\n<li>FDA Drugs@FDA: GEREF (sermorelin acetate) Injection, NDA 019863 <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&#038;ApplNo=019863\" target=\"_blank\" rel=\"noopener\">accessdata.fda.gov<\/a><\/li>\n<li>FDA Drugs@FDA: GEREF (sermorelin acetate) Injection, NDA 020443 <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&#038;ApplNo=020443\" target=\"_blank\" rel=\"noopener\">accessdata.fda.gov<\/a><\/li>\n<\/ol>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Key takeaways Whether a peptide is safe depends on its source: FDA-approved peptide drugs have measured side-effect rates in their labels, compounded peptides are not FDA-approved, and peptides sold online as research chemicals have no safety oversight at all. In the three placebo-controlled trials pooled in Wegovy&#8217;s label, which included 2,116 adults with obesity or [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":3913,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33],"tags":[],"class_list":["post-3912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity-wellness"],"acf":[],"_links":{"self":[{"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/posts\/3912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/comments?post=3912"}],"version-history":[{"count":1,"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/posts\/3912\/revisions"}],"predecessor-version":[{"id":3916,"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/posts\/3912\/revisions\/3916"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/media\/3913"}],"wp:attachment":[{"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/media?parent=3912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/categories?post=3912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revivelongevity.com\/ru\/wp-json\/wp\/v2\/tags?post=3912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}